Zimmer reveals the management team and business structure it plans to put in place once its $13 billion merger with rival Biomet closes.
Biomet agrees to pay more than $6 million to settle False Claims Act charges that it paid doctors to use its bone-growth stimulators.
Biomet paid nearly $6.1 million to settle federal charges that it paid kickbacks to doctors to induce them to use bone growth stimulators sold by its EBI subsidiary, the U.S. Justice Dept. said today.
Here's a look at some of the top regulatory stories for medical device companies this week: JNJ continues to pay hefty integration charges on Synthes deal; Stryker: Mako sales not as strong as we hoped; ConvaTec owners appoint banks to explore sale: sources; BD buys Irish next-gen sequencing startup GenCell Biosystems; Valeant says may raise Allergan bid; beats on profit
, Becton Dickinson & Co.
, DePuy Synthes
, GenCell Biosystems
, Johnson & Johnson
, Kimberly-Clark Worldwide Inc.
, MAKO Surgical Corp.
, Stryker Corp.
, Valeant Pharmaceuticals
, 3M Corp.
, Allergan Inc.
More than 2½ years after it spent $21.3 billion on Synthes, Johnson & Johnson continues to take hefty charges on integrating the orthopedics company into its DePuy franchise.
Profits during Biomet's fiscal 1st quarter plunge 77% despite nearly across-the-board sales increases for its orthopedic implants.
Biomet today reported a 77% profit slide for its fiscal 1st quarter, despite posting sales gains across its all but 1 line of orthopedic implants.
Here's a look at some of the top regulatory stories for medical device companies this week: Medtronic, Covidien name peripherals biz transition team; Medtronic is still in on Covidien buyout; The Street cheers changes to the Medtronic, Covidien deal; Zimmer adds Harvard spinout Etex Corp.; EU to extend Zimmer, Biomet probe
European anti-trust regulators are extending their probe into the proposed $13 billion merger of orthopedics rivals Zimmer and Biomet.
UPDATED Oct. 2, 2013, with comment from Zimmer.